Skip to main content

Health Canada announces third birth-control recall this year

Birth-control pills

Amanda Rohde/Thinkstock

Have the most recent recalls of birth control pills by Health Canada had an impact on you? If you would like to share your story, please contact cweeks@globeandmail.com.

Health Canada is warning Canadian women about another recall of birth-control pills – the third in recent months.

This time, the recall involves Esme-28, a generic brand of contraceptive medication sold by Mylan Pharmaceuticals. Last week, Mylan announced it was recalling Freya-28, another generic birth control, after one package was found to contain a placebo pill instead of active medication.

Story continues below advertisement

Health Canada said the newest recall is being done out of caution because Mylan has been "unable to rule out the possibility that Esme-28 was impacted" by the same placebo-pill issue that involved Freya-28.

The most recent recall will likely add to growing questions about the adequacy of quality control procedures used by manufacturers of birth-control pills.

Earlier this year, Health Canada and Apotex conducted a massive recall of Alysena-28, a generic birth-control pill, after a consumer found one placebo pill where an active pill should have been. Then-federal health minister Leona Aglukkaq had promised to investigate why the department did not issue a public warning about the problem with the birth-control pills until several days after it was identified. The Globe and Mail also reported that Apotex had been cited by the U.S. Food and Drug Administration for critical deficiencies at some of its manufacturing plants, and that the U.S. was threatening to halt imports from the company as a result.

Jennifer Blake, CEO of the Society of Obstetricians and Gynaecologists of Canada, a respected medical group, described the problems surrounding Alysena-28 as unacceptable and said it raises important questions about the company and Health Canada's quality-control processes and vigilance.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter